NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Subjects United States Remove constraint Subjects: United States Copyright Public domain Remove constraint Copyright: Public domain

Search Results

5. Data inadequacies undermine CMS's oversight of the inconsistency resolution process for the federal marketplace

6. CMS validated hospital inpatient quality reporting program data, but should use additional tools to identify gaming

8. CDC generally met its inspection goals for the federal select agent program: however, opportunities exist to strengthen oversight

10. Round 2 competitive bidding for CPAP/RAD: disrupted access unlikely for devices, inconclusive for supplies

12. OHRP generally conducted its compliance activities independently, but changes would strengthen its independence

13. HHS's Office of Refugee Resettlement improved coordination and outreach to promote the safety and well-being of unaccompanied alien children

14. Medicare program shared savings accountable care organizations have shown potential for reducing spending and improving quality

17. As funding for BPA research increased, NIEHS followed its peer review process while also exercising its discretion

19. Medicare Part B drug payments: impact of price substitutions based on 2014 average sales prices

21. Drug supply chain security: wholesalers exchange most tracing information

26. Enhancements needed in the tracking and collection of Medicare overpayments identified by ZPICS and PSCS

27. A few states fell short in timely investigation of the most serious nursing home complaints: 2011-2015

29. Medicare Part B drug payments: impact of price substitutions based on 2015 average sales prices

30. Medicare payments for clinical diagnostic laboratory tests in 2016: year 3 of baseline data

31. Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries

32. Medicaid Fraud Control Units: investigation and prosecution of fraud and beneficiary abuse in Medicaid personal care services

33. Followup review: CMS's management of the quality payment program

34. Potential misclassifications reported by drug manufacturers may have led to $1 billion in lost Medicaid rebates

35. Entities' experiences and perceptions of reporting the theft, loss, or release of select agents or toxins to CDC

36. Drug supply chain security: dispensers received most tracing information

38. Round two competitive bidding for oxygen: continued access for vast majority of beneficiaries

39. Round two competitive bidding for enteral nutrition: continued access for vast majority of beneficiaries

40. HRSA helped health centers with elevated risks and can continue to take additional steps

42. Part D plans generally include drugs commonly used by dual eligibles: 2018

44. Entities generally met Federal Select Agent Program internal inspection requirements, but CDC could do more to improve effectiveness

45. Opioid use in Medicare Part D remains concerning

46. CMS did not detect some inappropriate claims for durable medical equipment in nursing facilities

47. Opioids in Ohio Medicaid: review of extreme use and prescribing

50. Medicare Part B drug payments: impact of price substitutions based on 2016 average sales prices